A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Nitrite (Primary)
- Indications Burkholderia cepacia infections; Pseudomonal infections; Staphylococcal infections
- Focus Adverse reactions
- 13 Apr 2017 Dr. Ralph Panos is the lead investigator of this trial, according to an Arch Biopartners media release.
- 27 Feb 2017 New trial record
- 27 Oct 2016 According to Arch Biopartners media release, the application for this trial is expected to be submitted to the internal review board (IRB) of the CVAMC by December, 2016. IRB feedback is anticipated before January, 2017 and the trial is expected to start immediately upon an approval to proceed.